Miragen taps new COO
BOULDER — Oncology company MiRagen Therapeutics Inc. (Nasdaq: MGEN) has hired Lee Rauch as its new chief operating officer.
In a statement Thursday, the Boulder-based Miragen said Rauch will head up the company’s business development, licensing, communications and new product planning efforts.
I believe the current pipeline offers a number of clinical and preclinical stage programs ready for continued development, as well as for potential partnerships and licensing opportunities with the potential to drive long-term shareholder value,” Rauch said in a prepared statement.
SPONSORED CONTENT
Exploring & expressing grief
Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.
Rauch has held several positions as the head business-side executive for California clinical-stage pharmaceutical companies since 1999, with her most recent corporate post being chief business officer at Global Blood Therapeutics Inc. (Nasdaq: GBT) from October 2012 to March 2015, according to her LinkedIn biography.
From August 2015 to December 2019, she held mentoring and executive-in-residence roles at advisory firm Cervantes Life Partners LLC, holding company Fortress Biotech Inc. (Nasdaq: FBIO) and a venture program at Columbia University.
Miragen most recently presented positive patient longevity data for its Phase I trial of cobomarsen, a drug candidate being investigated for the potential to stop relapses in blood cancer survivors.
